![]() ![]() aspirin alone reduced cardiovascular death, heart attack or stroke by 14% and.the polypill alone reduced cardiovascular disease by 21%.The analysis of all patient groups found: Over the follow-up period of nearly five years, participants were monitored for the first occurrence of a major cardiovascular event, such as non-fatal heart attack, non-fatal stroke, heart failure, resuscitated cardiac arrest or cardiovascular death. The medications in the polypill were atenolol 100mg, ramipril 10mg, hydrochlorothiazide 25 mg, and simvastatin 40 mg. Each intervention included a control group who received a matching placebo. Participants were randomly assigned to different interventions: 1) 75 mg daily of aspirin 2) a polypill combining blood pressure and cholesterol medication daily 3) polypill and 75 mg aspirin daily or 4) vitamin D 5,000 IU daily. The average age of the participants was 64 years, and 47% were male. The study included 5,700 people considered at intermediate risk of developing heart disease. The International Polycap Study (TIPS)-3 is a large, randomized, placebo-controlled trial conducted in nine countries. They also examined the effects of aspirin alone. Researchers assessed the polypill’s effects on cardiovascular disease events – such as heart attack, stroke and cardiovascular death – when given alone or with aspirin, in patients considered at intermediate risk of cardiovascular disease. The medicine tested in this study is a fixed-dose combination therapy (or a “polypill”) combining blood pressure and cholesterol lowering medications. The manuscript of this study is simultaneously published today in The New England Journal of Medicine. The virtual conference, held Friday, November 13 - Tuesday, November 17, 2020, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide. 13, 2020 - A single, daily pill combining blood pressure and cholesterol medications, along with the addition of a daily dose of aspirin, reduced cardiovascular disease events in people at risk for heart disease, according to late-breaking research presented today in a late-breaking clinical trial presentation at the American Heart Association’s Scientific Sessions 2020. Results from the randomized, placebo-controlled trial show that the combination of a polypill plus aspirin reduced cardiovascular disease by 31%, and the polypill without aspirin reduced CVD by 21%.Įmbargoed until 12:10 p.m.In this large, international trial, the polypill included blood pressure and cholesterol lowering medications for people at risk for heart disease.A “polypill” is a single pill that includes multiple medications to control more than one health risk factor (such as heart disease, high blood pressure, high cholesterol, Type 2 diabetes, kidney disease, stroke).Our research team works side-by-side with patients, surgeons, nurses and with the input of the other members of the Department of Anesthesiology and Perioperative Medicine,” says Dr. “KGH was able to be a vital contributor to this important study due to the dedication of our excellent research nurses Debbie Dumerton-Shore, Jessica McCourt and Beth Orr, and my co-investigator René Allard. Devereaux (McMaster University’s Population Health Research Institute). The POISE-2 study was designed and led by Principal Investigator P. More than 400 patients were enlisted from KGH, making it the fourth-largest recruiting site in the world, after Hamilton Health Sciences Centre and The Cleveland Clinic. With over 10,000 patients from 23 countries and 135 centres, the study is the largest clinical trial to evaluate major cardiovascular complications in non-cardiac surgeries. “This is important news for the medical community and for patients with risk factors for heart disease who are set to undergo non-cardiac surgery.” “In fact, Aspirin was shown to increase the risk of serious bleeding after surgery, in some cases,” says Joel Parlow, Head of Anesthesiology and Perioperative Medicine at both Queen’s and KGH and the hospital’s POISE-2 Site Principal Investigator. Researchers Debbie Dumerton-Shore, Joel Parlow, Jessica McCourt and Rene Allard are part of a ground breaking study investigating the use of Aspirin to protect the heart after surgery. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |